Milsaperidone (VHX-896) vs Risperidone (Risperdal Consta)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Risperidone (Risperdal Consta)
Marketed by Johnson & Johnson
NCT00253136 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 458 participants, using change in a standard psychiatric symptom scale as the primary measure. The FDA product label for this pivotal trial reports that 47% of patients on the 25 mg dose showed a clinically meaningful improvement, compared with 17% on placebo.
Reported efficacy
Change from baseline to the end of double-blind treatment in the PANSS (Positive and Negative Syndrome Scale for Schizophrenia) total score: Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly. (met)
Result source: NCT00253136
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Milsaperidone (VHX-896) | Risperidone (Risperdal Consta) |
|---|---|---|
| PANSS total, change | —Not reported | -9.3 vs -1.1vs QuetiapineNCT002164761 other result
|
| CGI-S, change | —Not reported | -0.3 vs 0.1vs QuetiapineNCT002164761 other result
|
| PANSS response | —Not reported | —Not posted · NCT00216580 |
| PSP, change | —Not reported | 5.3 vs 6.0vs Risperidone TabletsNCT00992407 |
| Relapse (% of patients) | —Not reported | 5% vs 32.6%vs RisperidoneNCT003305511 other result
|
PANSS total, change
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Risperdal Consta)
- -9.3 vs -1.1vs QuetiapineNCT00216476
1 other result
- -11.7 vs -13 NCT00992407
CGI-S, change
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Risperdal Consta)
- -0.3 vs 0.1vs QuetiapineNCT00216476
1 other result
- -0.6 vs -0.7 NCT00992407
PANSS response
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Risperdal Consta)
- —Not posted · NCT00216580
PSP, change
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Risperdal Consta)
- 5.3 vs 6.0vs Risperidone TabletsNCT00992407
Relapse (% of patients)
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Risperdal Consta)
- 5% vs 32.6%vs RisperidoneNCT00330551
1 other result
- 34.4% vs 16.1% NCT00246259
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Risperidone (Risperdal Consta): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Risperidone (Risperdal Consta) |
|---|---|
| Dropout rate | 38.4%a NCT00132314 · Phase 3 show 14 more results5.9%CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 0%CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 14.3%HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 5.9%HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 25%Long-acting Injectable Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence —Long-acting Injectible Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence 29.5% NCT00539071 · Phase 4 · registry result, not featured evidence 83.8% NCT00992407 · Phase 4 · registry result, not featured evidence 26.5% NCT00130923 · Phase 4 · registry result, not featured evidence 31.8% NCT00216671 · Phase 4 · registry result, not featured evidence 63.6% NCT00246259 · Phase 4 · registry result, not featured evidence 67.5% NCT00269919 · Phase 4 · registry result, not featured evidence 45.3% NCT01726335 · Phase 4 · registry result, not featured evidence 31.9% NCT00216476 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00132314 · Phase 3 show 14 more results—CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence —CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence —HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence —HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence —Long-acting Injectable Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence —Long-acting Injectible Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence — NCT00539071 · Phase 4 · registry result, not featured evidence 18.9% NCT00992407 · Phase 4 · registry result, not featured evidence — NCT00130923 · Phase 4 · registry result, not featured evidence 5.5% NCT00216671 · Phase 4 · registry result, not featured evidence 11.4% NCT00246259 · Phase 4 · registry result, not featured evidence — NCT00269919 · Phase 4 · registry result, not featured evidence 7.5% NCT01726335 · Phase 4 · registry result, not featured evidence 1.8% NCT00216476 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 51.3%a NCT00132314 · Phase 3 show 14 more results18.8%CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 8.3%CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 8.3%HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 0%HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence —Long-acting Injectable Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence 5%Long-acting Injectible Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence 6.4% NCT00539071 · Phase 4 · registry result, not featured evidence 0% NCT00992407 · Phase 4 · registry result, not featured evidence 32.7% NCT00130923 · Phase 4 · registry result, not featured evidence 16.4% NCT00216671 · Phase 4 · registry result, not featured evidence 4.5% NCT00246259 · Phase 4 · registry result, not featured evidence 15.4% NCT00269919 · Phase 4 · registry result, not featured evidence 5.7% NCT01726335 · Phase 4 · registry result, not featured evidence 19.1% NCT00216476 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | show 13 more resultsbmi increase normal/overweight to obese 31.3% ldl or triglyceride increase 25% prolactin related symptom 12.5% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase normal/overweight to obese 25% prolactin related symptom 16.7% ldl or triglyceride increase 8.3% NCT00333177 · Phase 4 · registry result, not featured evidence ldl or triglyceride increase 41.7% prolactin related symptom 16.7% bmi increase normal/overweight to obese 0% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase normal/overweight to obese 12.5% ldl or triglyceride increase 6.3% prolactin related symptom 6.3% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase from normal or overweight to obese 17.5% prolactin related 7.5% lipid increase 5% NCT00330551 · Phase 4 · registry result, not featured evidence non-serious adverse events 16.7% NCT00539071 · Phase 4 · registry result, not featured evidence akathisisa 10% anxiety 10% muscle rigidity 10% NCT00992407 · Phase 4 · registry result, not featured evidence insomnia 10.2% pain 10.2% vomiting 10.2% NCT00130923 · Phase 4 · registry result, not featured evidence insomnia 8.2% akathisia 7.3% weight increased 7.3% NCT00216671 · Phase 4 · registry result, not featured evidence headache 34.1% insomnia 29.5% fatigue 25% NCT00246259 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 20.5% akathisia 12.8% vision blurred 10.3% NCT00269919 · Phase 4 · registry result, not featured evidence libido decreased 22.6% weight increased 13.2% blood prolactin increased 11.3% NCT01726335 · Phase 4 · registry result, not featured evidence hyperprolactinaemia 13.1% anxiety 11.9% insomnia 10.9% NCT00216476 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Risperidone (Risperdal Consta)
show 3 more results
show 7 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 7 more results
+ 33 further endpoints in the CSV export.
Bipolar Disorder
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Risperidone (Risperdal Consta)
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Bipolar Disorder
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.
Risperidone (Risperdal Consta): no structured comparison results are available for Bipolar Disorder.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Risperidone (Risperdal Consta)'s landscape